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Abstract. Inflammatory cytokines, matrix metalloproteinases
(MMPs) and cyclooxygenase (COX)‑2 released from rheumatoid arthritis synovial fibroblasts (RASFs) are involved in the
destruction of both articular bone and cartilage. Kaempferol
has been reported to act as an antioxidant and anti‑inflammatory agent by inhibiting nitric oxide synthase and COX
enzymes. The aim of the present study was to determine the
effects of kaempferol on the interleukin‑1β (IL‑1β)‑induced
proliferation of RASFs and the production of MMPs, COX
and prostaglandin E2 (PGE2) by RASFs. The proliferation
of the RASFs stimulated with IL‑1β and treated with/without
kaempferol was evaluated by CCK‑8 assay. The expression of
MMPs, TIMP metallopeptidase inhibitor‑1 (TIMP‑1), COXs,
PGE2 and that of intracellular MAPK signaling molecules,
including p‑ERK, p‑p38, p‑JNK and nuclear factor‑κB (NF‑κB)
was examined by immunoblotting or semi‑quantitative reverse
transcription‑polymerase chain reaction (RT‑PCR) and ELISA
under the conditions described above. Kaempferol inhibited
the proliferation of both unstimulated and IL‑1β‑stimulated
RASFs, as well as the mRNA and protein expression of MMP‑1,
MMP-3, COX‑2 and PGE2 induced by IL‑1β. Kaempferol also
inhibited the phosphorylation of ERK‑1/2, p38 and JNK, as
well as the activation of NF‑κB induced by IL‑1β. These results
indicate that kaempferol inhibits synovial fibroblast prolifera-
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tion, as well as the production of and MMPs, COX‑2 and PGE2,
which is involved in articular inflammation and destruction in
rheumatoid arthritis (RA). Our data suggest that kaempferol
may be a novel therapeutic agent for the treatment of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory systemic
disease of unknown etiology characterized by chronic
synovitis with subsequent articular bone and cartilage destruction (1,2). Chronic inflammation with hyperplasia of synovial
lining cells, including synovial fibroblasts, are the histological
characteristics of RA. When activated, rheumatoid arthritis
synovial fibroblasts (RASFs) play a key role in the pathogenesis of RA synovitis through proliferation and resultant pannus
formation. Inflammatory cytokines, matrix metalloproteinases (MMPs) and cyclooxygenase (COX)‑2 released from
RASFs are involved in the destruction of articular bone and
cartilage (1,2). On the basis that interleukin (IL)‑1β induces
the proliferation of RASFs, resulting in the production of high
levels of MMPs and prostaglandin E2 (PGE2), it has become a
major target of biological therapy.
Flavonoids are natural polyphenols present in a wide
variety of fruits and vegetables (3) and have a number of
biological properties, such as antiviral (4), antitumor (5), antioxidant (6) and anti‑inflammatory properties (7). Kaempferol
(3,5,7,4'‑tetrahydroxy flavone), which is found in tea, propolis
and grapefruit, is one of the most common dietary flavonoids (8).
It has been used as a traditional therapeutic for a number of
inflammatory disorders. Previous studies have demonstrated
that kaempferol reduces lipopolysaccharide‑induced COX‑2
levels in RAW 264.7 cells (9) and inhibits reactive oxygen
species production through the inhibition of inducible nitric
oxide synthase (iNOS) and tumor necrosis factor (TNF)‑α
protein expression in aged gingival tissues (10). Kaempferol has
also exhibited anti‑inflammatory effects through the inhibition
of IL‑4 (11), COX‑2 and C-reactive protein (CRP) expression
and the downregulation of nuclear factor‑κ B (NF‑κ B) in liver
cells (12). Despite these anti-inflammatory effects of kaempferol and the critical role of RASFs in RA pathogenesis, to our
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knowledge, there are no studies to date on the effects of kaempferol on inflammatory reactions, including the production of
MMPs, COX‑2 and PGE2 by RASFs.
In the present study, we investigated the effects of kaempferol on the production of pro-inflammatory mediators,
including MMPs, COX‑2 and PGE2 produced by RASFs and
the proliferation of these cells, following stimulation with
IL‑1β. Intracellular signaling factors were evaluated to elucidate the mechanisms behind the effects of kaempferol. We
demonstrate that kaempferol inhibits the IL‑1β‑induced proliferation of RASFs and inflammatory reactions by inhibiting the
activation of mitogen‑activated protein kinases (MAPKs) and
NF‑κ B pathways in RASFs.
Materials and methods
Reagents and antibodies. Recombinant human IL‑1β was
purchased from R&D Systems (Minneapolis, MN, USA) and
kaempferol were obtained from Sigma‑Aldrich, Inc. (St. Louis,
MO, USA) and dissolved in DMSO with a concentration
of 100 mM stock solution. Monoclonal antibodies (mAbs)
against COX‑2, MMP‑1, MMP‑3 and TIMP were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
mAbs against NF‑κB (p65), IkBα, ERK, p‑ERK, JNK, p‑JNK,
p38, p‑p38 and β‑actin were purchased from Cell Signaling
Technology (Beverly, MD, USA). Fetal bovine serum (FBS)
was obtained from Gibco BRL/Life Technologies (Grand
Island, NY, USA).
Isolation and culture of RASFs. Synovial tissues were
obtained at the time of total knee arthroplasty from patients
who fulfilled the American College of Rheumatology Criteria
for RA (13), as previously described (14). Synovial tissue
was digested for 2 h with 0.25% (w/v) collagenase and was
then suspended in RPMI‑1640 medium with 10% (v/v) FBS,
100 U/ml of penicillin and 100 µg/ml of streptomycin. The
cells were incubated at 37˚C in 5% CO2 for several days, after
which the non-adherent cells were removed. Synovial fibroblasts from passages 3‑7 were used for each experiment and
were morphologically homogeneous and had the appearance
of RASFs with typical fibroblastoid configuration under an
inverse microscope. The purity of the cells was determined
by flow cytometry using phycoerythrin (PE)‑conjugated
anti‑Thy‑1 (CD90) or anti‑CD14 and fluorescein isothiocyanate (FITC)‑conjugated anti‑CD3 mAb (BD Pharmingen, San
Diego, CA, USA). Informed consent was obtained from all
patients, and the study protocol was approved by the Chonbuk
National University Hospital Ethics Committee.
Cell viability analysis. Cell viability was determined by using
the Cell Counting Kit‑8 (CCK‑8; Dojindo Laboratories, Japan)
according to the manufacturer's instructions. CCK‑8 allows
convenient assays using Dojindo's tetrazolium salt, 2-(2methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)2H-tetrazolium, monosodium salt (WST‑8), which produces a
water‑soluble formazan dye upon bioreduction in the presence
of an electron carrier, 1‑methoxy phenazinium methylsulfate
(PMS) (15). CCK‑8 solution is added directly to the cells; no
pre‑mixing of the components is required. CCK‑8 is a sensitive
non-radioactive colorimetric assay for determining the number

of viable cells in cell proliferation and cytotoxicity assays.
WST‑8 is bioreduced by cellular dehydrogenases to an orange
formazan product that is soluble in tissue culture medium. The
amount of formazan produced is directly proportional to the
number of living cells. RASFs [1x105 cells/well in Dulbecco's
modified Eagle's medium (DMEM) containing 10% (v/v) FCS
in a 96‑well U‑bottom plate] were cultured in 200 µl medium/
well in the presence or absence of 1.0 ng/ml IL‑1β and/or
kaempferol (100 µM) for 2 days according to the results of a
dose‑dependent examination and a previous report (15), while
the control RASFs were incubated in DMEM with DMSO.
CCK‑8 (20 µl) was added to each well of the plate and the cells
were incubated for 2‑3 h. The absorbance was measured at
450 nm using a microplate reader to determine the cell viability
in each well.
Analysis of apoptosis. To evaluate the effects of kaempferol
on the apotosis of RASFs, RASFs were incubated in DMEM
for 24 h with kaempferol (100 µM), while the control RASFs
were incubated in DMEM with DMSO. The cells were then
trypsinized and collected for the detection of apoptosis with
an Annexin V‑FITC Apoptosis Detection kit according to the
manufacturer's instructions. Briefly, the cells were washed
twice with cold PBS and resuspended in 500 ml of binding
buffer (10 mM HEPES‑NaOH pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2) at a concentration of 0.5x105 cells/ml. After the addition
of 5 µl of Annexin V‑FITC solution and propidium iodide (PI;
5 µl), the cells were incubated for 15 min at room temperature.
The cells were analyzed using a flow cytometer (Beckman
Coulter, Fullerton, CA, USA).
RNA isolation and semi-quantitative reverse transcription‑polymerase chain reaction (RT‑PCR( of COX, MMPs
and TIMP. Total RNA was extracted from the cultured RASFs
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
following the manufacturer's instructions. RNA (1 µg) was
reverse‑transcribed using the Maxime RT Premix kit (iNtRON
Biotechnology, Seoul, Korea). cDNA was amplified using the
following primer sets: MMP‑1 sense, 5'‑GAA GGA GAT
GAA GCA GCC CAG ATG T‑3' and antisense, 5'‑CAG TTG
TGG CCA GAA AAC AGA AGT GAA A‑3'; MMP‑3 sense,
5'‑GAC ACC AGC ATG AAC CTT GTT‑3' and antisense,
5'‑GGA ACC GAG TCA GGA CTA TG‑3'; TIMP‑1 sense,
5'‑CCT TCT GCA ATT CCG ACC TCG TC‑3' and antisense,
5'‑CGG GCA GGA TTC AGG CTA TCT GG‑3'; COX‑2
sense, 5'‑TCC TTG CTG TTC CCA CCC ATG‑3' and antisense, 5'‑CAT CAT CAG ACC AGG CAC CAG‑3'; GAPDH
sense, 5'‑AAA TCA AGT GGG GCG ATG CT‑3' and antisense, 5'‑AGC TTC CCG TTC AGC TCA GG‑3'. PCR
products were electrophoresed using 1% agarose gels and
visualized by staining with ethidium bromide. Densitometric
analysis was performed on the relative intensity of each band
using the Multi Gauge software v3.0 (Fujifilm, Tokyo, Japan).
Immunoblotting. RASFs (1x106 cells) were seeded on 100‑mm
culture dishes and harvested in phosphate-buffered saline
(PBS). After washing with PBS, cell pellets were lysed with
the lysis buffer [20 mM HEPES, pH 7.2, 1% Triton X‑100,
150 mM NaCl, 0.1 mM phenylmethylsulfonyl fluoride (PMSF),
1 mM EDTA and 1 µg/ml aprotinin]. Following incubation for
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Figure 1. Interleukin‑1β (IL‑1β) increases the proliferation of rheumatoid arthritis synovial fibroblasts (RASFs) in a dose‑dependent manner and kaempferol
inhibits the IL‑1β ‑induced proliferation of RASFs. (A) To determine the effects of kaempferol on the IL‑1β ‑induced proliferation of RASFs, kaempferol
(100 µM) was added to the RASF cultures with/without IL‑1β (1.0 ng/ml) for 3 days and CCK‑8 assay was performed. Kaempferol significantly inhibited the
IL‑1‑induced proliferation of RASFs after 2‑3 days of culture (P<0.05). *P<0.05 vs. no IL‑1β and kaempferol (control), #P<0.05 vs. IL‑1β without kaempferol.
(B) To determine the dose‑dependent effects of kaempferol on the IL‑1β‑induced proliferation of RASFs, various doses of kaempferol (10, 50, 100 and 200 µM)
were added to the RASF cultures with IL‑1β (1.0 ng/ml) for 2 days and CCK‑8 assay was performed. Kaempferol inhibited the IL‑1β‑induced proliferation
of RASFs in a dose‑dependent manner. *P<0.05 vs. no IL‑1β and kaempferol, #P<0.05 vs. IL‑1β without kaempferol, ##P<0.01 vs. IL‑1β without kaempferol.

30 min at 4˚C, cellular debris was removed by centrifugation
at 100,000 x g for 30 min and the supernatants were analyzed
by sodium dodecyl sulfate‑polyacrylamide gel electrophoresis
(SDS‑PAGE). To determine membrane COX‑2 expression in
RASFs, cell membranes were prepared from isolated RASFs
as previously described (16). To determine NF‑κ B (p65)
expression, nuclear extracts were prepared using a previously described method (14). To determine cytoplasmic IkBα
expression, cytoplasmic extracts were prepared as previously
described (14).
Protein concentration was determined using the Bio‑Rad
protein assay reagent (Bio‑Rad Laboratories, Hercules, CA,
USA). Samples (50 µg) were prepared with 4 vol of 0.5 M
Tris buffer (pH 6.8) containing 4% SDS, 20% glycerol and
0.05% bromophenol blue at 95˚C for 5 min. SDS‑PAGE was
performed on a 10% slab gel. Proteins were transferred onto
a nitrocellulose membrane. The membrane was washed in
blocking buffer (10 mM Tris‑HCl pH 8.0, 150 mM NaCl, 5%
fat‑free milk) for 60 min at room temperature with shaking
and then washed with TBST (TBS, 0.01% Tween‑20). Primary
antibodyies (10 µg/ml) against MMP‑1, MMP‑3, TIMP, COX‑2,
ERK, p‑ERK‑1/2, p‑38, p‑p38 MAPK, JNK, p‑JNK, NF‑κ B
(p65), IkBα and β‑actin were then added followed by incubation at 4˚C for 4 h. The secondary HRP‑conjugated antibody
was goat anti‑mouse IgG (Santa Cruz Biotechnology, Inc.).
Reactive proteins were detected by enhanced chemiluminescence (ECL; Amersham Life Sciences, Arlington Heights, IL,
USA) using Fujifilm LAS‑3000 (Fujifilm).
Assay of PGE2 production. RASFs (1x104 cells) were grown
in 25 cm2 tissue‑culture flasks for 48 h before treatment. After
washing with PBS (pH 7.4), cells were pre-treated with IL‑1β
(1.0 ng/ml) or kaempferol (100 µM) at 37˚C for 48 h in DMEM
containing 10% (v/v) FCS in an atmosphere of 5% CO2, while
the control RASFs were incubated in DMEM with DMSO. The
culture supernatant described above was collected at 2 days.
The level of PGE2 in the medium was determined by ELISA
(R&D Systems) in accordance with the instructions of the
manufacturer.

Statistical analysis. All data are expressed as the means ± SD
of the results of 3 experiments with different RASFs and all
data were analyzed using SPSS 12.0 software. Group mean
values were compared using the Student's t‑test or ANOVA
where appropriate. P‑values <0.05 were considered to indicate
statistically significant differences.
Results
Kaempferol inhibits the IL‑1β‑induced proliferation of RASFs.
The effect of kaempferol on the growth ability of RASFs was
initially evaluated. Cell proliferation was measured following
treatment with IL‑1β for 3 days; IL‑1β is a well known potent
growth‑promoting factor for RASFs (17). Cell proliferation
was assayed as described in Materials and methods. IL‑1β
increased the proliferation of RASFs in a dose‑dependent
manner (from 0.1 to 10 ng/ml). To examine the effects of
kaempferol on the IL‑1β ‑induced proliferation of RASFs,
kaempferol (100 µM) was added to the RASF cultures with/
without IL‑1β (1.0 ng/ml) for 2 days and the CCK‑8 assay was
performed. IL‑1β significantly increased the proliferation of
RASFs compared with the control cells cultured in DMSO
without IL‑1β and kaempferol (P<0.05) (Fig. 1A). Kaempferol
significantly inhibited the proliferation of RASFs treated with
or without IL‑1β (P<0.05). Various doses of kaempferol (10,
50, 100, 200 µM) were added to the RASF cultures with IL‑1β
(1.0 ng/ml) for 2 days and CCK‑8 assay was performed. The
inhibitory effects of kaempferol were significantly enhanced
in a dose‑dependant manner (Fig. 1B).
Kaempferol induces the apoptosis of RASFs. To elucidate
the underlying mechanisms by which kaempferol inhibits
the IL‑1β ‑induced proliferation of RASFs, the effects of
kaempferol on the apoptosis of RASFs were examined by flow
cytometry and staining with Annexin V and PI. The percentage
of Annexin V‑positive cells was significantly increased in
the RASFs treated with kaempferol compared with the cells
cultured in DMEM with DMSO without kaempferol (P<0.05)
(Fig. 2).
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Figure 2. Kaempferol induces the apoptosis of rheumatoid arthritis synovial fibroblasts (RASFs). To determine the exact cause of the decreased proliferation
induced by kaempferol, the effects of kaempferol on the apoptosis of RASFs were investigated by flow cytometry. RASFs (1x105) were cultured in 33‑mm dishes
in DMEM with DMSO in the presence or absence of kaempferol (100 µM). Following culture for 24 h, the cells were stained with Annexin V and propidium
iodide (PI) and analyzed by flow cytometry. Kaempferol increased the apoptosis of RASFs compared with the control cells cultured in DMSO without kaempferol. *P<0.05 vs. no kaempferol.

Figure 3. Kaempferol inhibits interleukin‑1β (IL‑1β)‑induced production of matrix metalloproteinases (MMPs) and cyclooxygenase (COX)‑2 in rheumatoid arthritis synovial fibroblasts (RASFs). To determine the mRNA and protein expression of MMP‑1, MMP‑3, TIMP‑1 and COX‑1 and COX‑2, RASFs
(1x106 cells) were cultured for 2 days with/without IL‑1β (1.0 ng/ml) and kaempferol (100 µM). RNA and protein were extracted from the RASFs and analyzed
by (A) RT‑PCR and (B) western blot analysis. IL‑1β enhanced the protein expression of MMP‑1, MMP‑3, TIMP‑1 and COX‑2 compared with the cells cultured
without IL‑1β. Kaempferol inhibited the IL‑1β‑induced protein expression of MMP‑1, MMP‑3 and COX‑2. Results are presented as the means ± SD. n=3.
*
P<0.05 or **P<0.01 vs. no IL‑1β and kaempferol, #P<0.05 vs. no IL‑1β and kaempferol, ##P<0.05 vs. IL‑1β without kaempferol.

Effects of kaempferol on IL‑1β ‑induced MMP, TIMP‑1 and
COX mRNA expression in RASFs. RT‑PCR was performed
to determine the mRNA expression of MMP‑1, MMP-3 and
TIMP‑1 in the monocultured RASFs. RASFs were stimulated
with IL‑1β (1.0 ng/ml) for 48 h in the presence or absence of
kaempferol (100 µM). IL‑1β enhanced the mRNA expression of MMP‑1 and MMP‑3 in RASFs (P<0.05), but not that
of TIMP‑1. Kaempferol inhibited the effects of IL‑1β on the

mRNA expression of MMP‑1 and MMP‑3 (P<0.05) (Fig. 3A).
IL‑1β also enhanced the mRNA expression of COX‑2 in
RASFs (P<0.01), but not that of COX‑1 (data not shown).
Kaempferol inhibited the IL‑1β ‑induced COX‑2 mRNA
expression (P<0.05) (Fig. 3A). Kaempferol also significantly
decreased the mRNA expression of MMP‑1, MMP‑3 and
COX‑2 compared with the control cells cultured in DMSO
without IL‑1β and kaempferol (P<0.05).
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Figure 4. Prostaglandin E2 (PGE2) production was inhibited by treatment with
kaempferol. Rheumatoid arthritis synovial fibroblasts (RASFs; 1x104 cells)
were grown in 25 cm2 tissue‑culture flasks for 48 h and were starved serum
overnight prior to stimulation. RASFs were cultured for 2 days with/without
interleukin (IL)‑1β (1.0 ng/ml) and kaempferol (100 µM). The production
of PGE2 by RASFs was evaluated by ELISA. IL‑1β‑induced PGE2 production was significantly inhibited by kaempferol. Results are presented as the
means ± SD, n=3, *,#P<0.05 vs. no IL‑1β and kaempferol, ##P<0.05 vs. IL‑1β
without kaempferol.

Effects of kaempferol on IL‑1β ‑induced MMP, TIMP‑1 and
COX protein expression in RASFs. To determine the protein
expression of MMPs, TIMP‑1 and COX in the monocultured
RASFs, we performed western blot analysis. RASFs were
stimulated with IL‑1β (1.0 ng/ml) for 48 h in the presence or
absence of kaempferol (100 µM). IL‑1β enhanced the protein
expression of MMP‑1 and MMP‑3 in RASFs (P<0.05), but
not that of TIMP‑1; its effects on protein expression were
similar to those on mRNA expression. Kaempferol inhibited
the IL‑1β‑induced protein expression of MMP‑1 and MMP‑3
(P<0.05) (Fig. 3B). IL‑1β also enhanced the protein expression of COX‑2 in RASFs (p < 0.01), but not that of COX‑1
(data not shown). Kaempferol inhibited the IL‑1β ‑induced
protein expression of COX‑2 (P<0.05) (Fig. 3B). Kaempferol
also significantly decreased the protein expression of MMP‑1,
MMP‑3 and COX‑2 compared with the control cells cultured
in DMSO without IL‑1β and kaempferol (P<0.05).
Kaempferol inhibits IL‑1β ‑induced PGE2 production in
RASFs. To confirm the effects of kaempferol on the IL‑1β induced production of PGE2 by RASFs, we examined the
concentration of PGE2 in the culture supernatant. RASFs
(1x10 4 cells) were grown in 25 cm 2 tissue‑culture flasks
for 48 h before and after treatment with IL‑1β (1.0 ng/ml)
and/or kaempferol (100 µM). PGE2 production was increased
following treatment with IL‑1β (P<0.05) compared with the
control cells cultured with DMSO without IL‑1β, and it was
significantly inhibited by treatment with kaempferol at 48 h
(P<0.05) (Fig. 4); the effects of kaempferol on PGE2 were
similar to those on COX‑2 expression. Kaempferol also significantly decreased the production of PGE2 compared with the
control cells cultured in DMSO without IL‑1β and kaempferol
(P<0.05) (Fig. 4).
Effects of kaempferol on IL‑1β ‑induced signaling pathways
in RASFs. To demonstrate the involvement of the signal transduction pathways and to elucidate the mechanisms behind the
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effects of kaempferol on IL‑1β‑induced RASF proliferation
and the production of MMPs, COX‑2 and PGE2, the activation of MAPKs and NF‑κB was evaluated in the RASFs. IL‑1β
phosphorylated intracellular MAPKs, including ERK, p‑38 and
JNK and kaempferol significantly inhibited the IL‑1β‑induced
intracellular MAPK activation (Fig. 5A). The activation of
NF‑κ B, p65 and the degradation of cytoplasmic IkBα was
observed in the RASFs treated with IL‑1β. The effects of IL‑1β
on NF‑κ B activation were abrogated by kaempferol (Fig. 5B).
Kaempferol also inhibited the activation of the above intracellular signaling pathways compared with the control cells
cultured in DMSO without IL‑1β and kaempferol. These results
indicate that kaempferol inhibits the IL‑1β‑induced proliferation of RASFs, the expression of COX‑2 and the production of
PGE2 by inhibiting the activation of intracellular MAPK and
NF‑κB pathways.
Discussion
In this study, we demonstrate that kaempferol induces the
apoptosis of RASFs and inhibits the IL‑1β‑induced proliferation of RASFs. It inhibits the activation of the MAPK, ERK1/2,
p‑38 and JNK and NF‑κ B signaling pathways, resulting in the
decreased expression of MMPs and COX‑2, as well as in the
decreased production of PGE2 by RASFs. These findings
suggest that kaempferol may be used as a novel therapeutic
agent for the management of RA by decreasing synovial
inflammation.
Kaempferol, a polyphenolic flavonoid extracted from fenugreek seeds, has been shown to have strong antioxidant and
anti‑inflammatory properties (18). Previous studies have demonstrated that kaempferol reduces lipopolysaccharide‑induced
COX‑2 levels in RAW 264.7 cells (9) and inhibits reactive oxygen
species production through the inhibition of iNOS and TNF‑α
protein expression in aged gingival tissues (10). Kaempferol has
also exhibited anti‑inflammatory effects through the inhibition
of IL‑4 (11), COX‑2 and CRP expression and the downregulation
of NF‑κB in liver cells (12). Compared with other daily dietary
flavonols, kaempferol has been reported to be associated with
a decreased risk of various types of cancer (19‑21). However,
to our knowledge, there are no reports to date on the effects of
kaempferol on inflammatory reactions, including the production
of MMPs, COX‑2 and PGE2 by RASFs and the mechanisms
involved, which play a crucial role in the pathogenesis of synovitis and articular destruction in RA.
In RA, one of the most striking features is the hyperplasia
of synovial fibroblasts in the lining layer which is considered
to be the main mechanism responsible for the hyperplasic
growth of the RA synovium and eventually destroys articular
bone and cartilage (22,23). Given that the IL‑1β ‑induced
proliferation of RASFs is closely involved in inflammatory
synovitis joint destruction, the response of RASFs to IL‑1β
plays a crucial role in the physiopathology of RA (24). Our
study demonstrated that kaempferol significantly induced
the apoptosis of RASFs and inhibited the proliferation of
unstimulated and IL‑1β‑stimulated of RASFs in a dose‑ and
time‑dependent manner.
Pro-inflammatory cytokines, including IL‑1β enhance the
expression of COX‑2 and MMPs in human RASFs (25,26).
MMPs are involved in the destruction of the extracellular
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Figure 5. Effects of kaempferol on the interleukin‑1β (IL‑1β)‑induced activation of mitogen‑activated protein kinase (MAPK) signaling pathways and nuclear
factor‑κ B (NF‑κ B) activation in rheumatoid arthritis synovial fibroblasts (RASFs). To evaluate the mechanisms behind the effects of kaempferol on IL‑1β in
RASFs, MAPK signaling pathways (ERK, p38 and JNK) and NF‑κ B and Iκ Bα were evaluated by immunoblotting. RASFs were cultured for 10 min with/without
IL‑1β (1.0 ng/ml) and kaempferol (100 µM). IL‑1β enhanced the phosphorylation of ERK, p38 and JNK and kaempferol inhibited the IL‑1β‑induced activation of
p38 and JNK (A). IL‑1β activated nuclear NF‑κ B and decreased cytoplasmic IkBα and kaempferol inhibited the IL‑1β‑induced activation of NF‑κ B (B). Results
are presented as the means ± SD, n=3; *P<0.01 vs. no IL‑1β‑and kaempferol, #P<0.05 vs. IL‑1β without kaempferol.

matrix in articular structures and COX‑2 converts free arachidonic acid into prostaglandins, including a variety of bio‑active
compounds [prostacyclin (PGI2), thromboxane A2 (TXA2),
PGE2 and prostaglandin D2 (PGD2)]. PGE2, a pleiotropic
mediator of inflammation, is involved in several pathological
processes and plays a critical role in eliciting the signs and
symptoms of inflammation in the joints of RA patients when
produced in excess (27). We also found that kaempferol
inhibits the expression of MMPs and COX‑2 and PGE2
synthesis in a dose‑dependent manner in both unstimulated
and IL‑1β‑stimulated RASFs. This suggests that kaempferol
may be a potent therapeutic compound for RA. However,
further studies are required to investigate the overall effects
of kaempferol on the pathophysiology of synovitis in in vivo
systems, such as animal models of RA and collagen‑induced
arthritis (CIA) and to elucidate the underlying mechanisms.
NF‑κ B�����������������������������������������������
and MAPKs participate in the pathogenic mechanisms of inflammation and the destruction of joints in RA.
It is known that NF‑κ B, JNK, p‑38 and ERK are expressed
in cultured RASFs and are readily activated by IL‑1β and
TNF‑α (13,28,29). Numerous studies have demonstrated that
inhibitors of MAPKs or NF‑κ B����������������������������
decrease synovial inflammation, bone destruction and cartilage damage in animal models
of arthritis, including adjuvant arthritis in rats and CIA in
mice (30,31). It has been described that kaempferol suppresses

IL‑1β‑induced inflammatory responses by regulating signaling
pathways, including NF‑κ B��������������������������
activation and MAPK phosphorylation in human airway epithelial cells (32). In human
synovial cells, the addition of kaempferol has been shown to
suppress the TNF‑α‑induced increase in the mRNA expression of IL‑8 and monocyte chemotactic protein-1 (MCP‑1) in a
dose-dependent manner by inhibiting the activation of NF‑κ B
induced by TNF‑α (33). In this study, to elucidate the mechanisms behind the effects of kaempferol on IL‑1β ‑induced
RASF proliferation, the expression of COX‑2 and the production of PGE2, as well as the activation of MAPKs and NF‑κ B
were examined. Our results revealed that kaempferol inhibited
the IL‑1β‑induced activation of NF‑κ B���������������������
and the phosphorylation of ERK, p‑38 and JNK. However, further investigations
are required to elucidate the mechanisms by which kaempferol
suppresses NF‑κ B activation, which components of NF‑κ B are
suppressed, and which intracellular signaling factors are more
specifically or directly involved in the effects of kaempferol on
the proliferation of RASFs and PGE2 production.
To our knowledge, this is the first study to report that
kaempferol induces the apoptosis of RASFs and inhibits the
IL‑1β‑induced proliferation of RASFs. It also suppresses the
expression of MMP‑1, MMP‑3 and COX‑2 and the production
of PGE2 by RASFs by inhibiting the IL‑β‑induced activation
of NF‑κ B and the phosphorylation of the MAPK pathways,
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p‑38, JNK and ERK. Based on our findings, kaempferol has
great potential as a novel therapeutic agent and may prove
useful in the treatment of inflammatory diseases, including
RA. However, further studies are required to elucidate the
exact mechanisms underlying the inhibitory effects of kaempferol on synovial cell proliferation and inflammatory reactions.
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